- Home
- FLO vs BEAM Comparison
FLO vs BEAM Comparison
Compare FLO & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLO
- BEAM
- Stock Information
- Founded
- FLO 1919
- BEAM 2017
- Country
- FLO United States
- BEAM United States
- Employees
- FLO N/A
- BEAM N/A
- Industry
- FLO Packaged Foods
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FLO Consumer Staples
- BEAM Health Care
- Exchange
- FLO Nasdaq
- BEAM Nasdaq
- Market Cap
- FLO 3.2B
- BEAM 2.6B
- IPO Year
- FLO N/A
- BEAM 2020
- Fundamental
- Price
- FLO $11.93
- BEAM $25.01
- Analyst Decision
- FLO Hold
- BEAM Strong Buy
- Analyst Count
- FLO 4
- BEAM 11
- Target Price
- FLO $16.50
- BEAM $49.40
- AVG Volume (30 Days)
- FLO 3.1M
- BEAM 2.6M
- Earning Date
- FLO 11-06-2025
- BEAM 11-05-2025
- Dividend Yield
- FLO 8.20%
- BEAM N/A
- EPS Growth
- FLO 71.08
- BEAM N/A
- EPS
- FLO 1.04
- BEAM N/A
- Revenue
- FLO $5,098,751,000.00
- BEAM $60,272,000.00
- Revenue This Year
- FLO $4.24
- BEAM N/A
- Revenue Next Year
- FLO $0.04
- BEAM $19.01
- P/E Ratio
- FLO $11.47
- BEAM N/A
- Revenue Growth
- FLO N/A
- BEAM N/A
- 52 Week Low
- FLO $11.89
- BEAM $13.53
- 52 Week High
- FLO $23.04
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- FLO 30.01
- BEAM 47.97
- Support Level
- FLO $12.73
- BEAM $26.90
- Resistance Level
- FLO $12.87
- BEAM $28.71
- Average True Range (ATR)
- FLO 0.25
- BEAM 2.00
- MACD
- FLO -0.01
- BEAM -0.59
- Stochastic Oscillator
- FLO 3.28
- BEAM 18.78
About FLO Flowers Foods Inc.
Flowers Foods Inc is an American company producing bakery food for retail and foodservice across the United States. The product portfolio includes fresh breads, buns, rolls, snack cakes, and tortillas. The company distributes to supermarkets, convenience stores, and restaurants. The key brands are Nature's Own, Wonder, Tastykake, Canyon Bakehouse, DKB.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.